Anonymous ID: 000000 Jan. 27, 2023, 10:51 p.m. No.18241177   🗄️.is đź”—kun   >>1190 >>1206 >>1671 >>1745

>>18241170

Download now

Download hide.me VPN

Secure all your devices

No signup required

No Speed limits

Get Free VPNShow/hide

Search

 

Hamburger

Pfizer Responds to Research Claims

Friday, January 27, 2023 - 08:00pm

New York, N.Y., January 27, 2023 – Allegations have recently been made related to gain of function and directed evolution research at Pfizer and the company would like to set the record straight.

 

In the ongoing development of the Pfizer-BioNTech COVID-19 vaccine, Pfizer has not conducted gain of function or directed evolution research. Working with collaborators, we have conducted research where the original SARS-CoV-2 virus has been used to express the spike protein from new variants of concern. This work is undertaken once a new variant of concern has been identified by public health authorities. This research provides a way for us to rapidly assess the ability of an existing vaccine to induce antibodies that neutralize a newly identified variant of concern. We then make this data available through peer reviewed scientific journals and use it as one of the steps to determine whether a vaccine update is required.

 

In addition, to meet U.S. and global regulatory requirements for our oral treatment, PAXLOVID™, Pfizer undertakes in vitro work (e.g., in a laboratory culture dish) to identify potential resistance mutations to nirmatrelvir, one of PAXLOVID’s two components. With a naturally evolving virus, it is important to routinely assess the activity of an antiviral. Most of this work is conducted using computer simulations or mutations of the main protease–a non-infectious part of the virus. In a limited number of cases when a full virus does not contain any known gain of function mutations, such virus may be engineered to enable the assessment of antiviral activity in cells. In addition, in vitro resistance selection experiments are undertaken in cells incubated with SARS-CoV-2 and nirmatrelvir in our secure Biosafety level 3 (BSL3) laboratory to assess whether the main protease can mutate to yield resistant strains of the virus. It is important to note that these studies are required by U.S. and global regulators for all antiviral products and are carried out by many companies and academic institutions in the U.S. and around the world.

 

Fact-based information rooted in sound science is vitally important to overcoming the COVID-19 pandemic and Pfizer remains committed to transparency and helping alleviate the devastating burden of this disease.

Anonymous ID: 000000 Jan. 27, 2023, 11:09 p.m. No.18241220   🗄️.is đź”—kun

>>18241081

01110011 01101000 01110101 01110100 00100000 01110100 01101000 01100101 00100000 01100110 01110101 01100011 01101011 00100000 01110101 01110000 00100000 01111001 01101111 01110101 00100000 01100100 01110101 01101101 01100010 00100000 01101110 01101001 01100111 01100111 01100101 01110010